Vaccine-Related Injuries May Be Related to Truncated mRNA (Part 2)

An investigation into mRNA quality issues

The European Medicines Agency (EMA) has raised significant concerns about the impurity of truncated mRNA found in Pfizer’s COVID-19 vaccine samples. Truncated mRNA molecules are a dire issue because changes to the specific protein-coding sequence could result in unexpected proteins and consequences in human cells.

In Part 1 of this series, we reviewed the evidence that the Pfizer COVID-19 vaccine contains mRNA fragments or truncated mRNA. We explained that this is a serious issue on top of the vaccine’s life-threatening safety events. We also uncovered that Pfizer had submitted falsified mRNA analytical reports to multiple health authorities.

In this, Part 2, we will discuss the potential vaccine-related injuries that might be brought about by truncated mRNA of the Pfizer vaccine; we will also discuss the root cause of inaction by the health authorities.

Summary of Key Facts

  • Truncated mRNA and related quality issues of the Pfizer mRNA vaccine could cause severe adverse health effects.
  • Truncted mRNA is a serious quality issue for COVID-19 mRNA vaccines.
  • A lack of uniformity in vaccine batches contributes to the disparity of adverse events experienced by those who have received the vaccine.
  • The root cause behind these vaccine issues is a moral failure.

Before March 2021, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) demanded that Pfizer address the potential detrimental outcome of truncated mRNAs but instead received falsified Western blots, as detailed in the previous article.

Pfizer did not provide a truthful answer to the EMA, yet the EMA wrote that these specific obligations were “considered solved.” Considered by whom?

Most Truncated mRNA in the Pfizer Vaccine Is Missing a Stop Codon

A full-length mRNA contains five parts:

  • 5’ CAP function—primes its translation
  • 5’ UTR—does not translate into protein sequence
  • Coding region—will be translated into protein sequences
  • 3’ UTR—does not translate into protein sequence; a stop codon is at the beginning of this region
  • Poly(A) tail—increases the stability of the mRNA

At the beginning of the 3’ UTR, there is a stop codon, which is also the stop signal of the open reading frame of mRNA.

Pfizer’s mRNA vaccine’s total length is 4,284 nucleotides long. As the Poly(A) tail spans from nucleotides 4,175–4,284, 3’ UTR spans from nucleotides 3,880–4,174, so the stop codon position is at 3,877–3,879. As most of the truncated mRNA is shorter than 3,500 nucleotides per the EMA reports, most of the impure mRNA does not contain a stop codon.

People may argue that such truncated mRNA does not have a Poly(A) tail, so it is not stable and should degrade quickly. Pfizer has submitted materials to demonstrate that no truncated proteins have been generated.

This might be true for a certain amount of mRNA added into a single in vitro cellular system. However, the in vitro data cannot be translated into human results. Things would become complicated if truncated mRNA were embedded in well-designed lipid nanoparticles and injected into a human body.

1. Abnormal Fibrous Clots Induced Heart Attacks, Strokes, and Deaths

As there is no stop signal, in theory, another mRNA in a cell will take over and continue to prolong the “spike protein.” If the same spike mRNA takes over, prolonged spike-like proteins with multiple repeats will form. If different mRNA takes over, unknown types of proteins will form.

By mid-2021, embalmers worldwide pulled odd, white, or brown fibrous clots from dead bodies, which were not reported before.

They are string-like shapes a few inches to several feet long. They are often rubbery and firm, All these features show that they are very different from normal blood clots, which are normally soft, round, flat, and clump-like, with dark red to black color.

Even though we have summarized research evidence to understand the mechanisms of those strange clots, still there seems to be something missing here to fully understand the driver behind the unusual length of those clots.

What if the string-like structure of spike protein grows longer when there is no stop signal? That could help explain why embalmers discovered those unusually long fibrous clots during autopsies.

The “spike proteins” present seven amyloidogenic sequences and can form amyloid-like substances. Such structures make it easy to form tighter string-like bonded structures with longitudinal twisting and cross-binding, forming a fibrous-like structure. An analogy of this process is making hemp rope: short and slim hemp fibers can be rolled into long, strong ropes with high force resistance.

With the “stop codon” missing from truncated mRNA, the starting material (like the “hemp fibers”) could be longer than normal spike protein. After several rounds of twisting and cross-binding, it would be not a surprise to form those unusual lengthy fibrous clots.

Epoch Times Photo

Of course, other situations could explain the formation of those strange spike-related blood clots. However, until today, truncated mRNA without a “stop mechanism” in the translation process of spike proteins remains one of the most likely drivers forming such lengthy fibrous clots in people’s blood vessels.

Meanwhile, spike protein can also trigger the clotting cascade by inducing endothelial disruptioninflammation of endothelial cells, life-threatening thrombotic complicationshyperactivating platelets via multiple receptors (ACE2, TMPRSS2, or fibronectin receptor), fibrous networks from neutrophil extracellular traps (NETs), as well as increasing angiotensin II levelactivating Toll-like receptor 4, and increasing coagulation factor (FXa) production,

2. Neurodegenerative Conditions

In healthy cells, truncated mRNA and defective proteins can be recognized and eliminated by protein quality control pathways in our body.

Depending on the protein and the efficiency of the protein quality control system, however, such aberrant proteins can escape our body’s quality control system, misfold, form insoluble aggregates, impair the ability of healthy cell function, and lead to many diseases, including Alzheimer’s and Parkinson’s.

In addition, the vaccine fog syndrome could be at least partially correlated with the outcome of these truncated mRNA-derived proteins.

3. Cancers

This quality issue may provide insights into the observation of a 2022 study conducted at Lund University in Sweden, showing that the Pfizer-BioNTech mRNA vaccine could “reverse transcribe” six hours after entering human liver cells and affecting human genes.

Epoch Times Photo
mRNA vaccine may change human DNA. (MDPI)

Currently, most cancers are considered to be caused by gene mutation and damage.

Accordingly, it also helps explain American pathologist Dr. Ryan Cole’s observation of an abnormal, disturbing increase in certain cancer cases after receiving the COVID-19 vaccine.

Recently, Cole shared the biopsy results of a patient with multiple myeloma, showing that most B-cells have spike protein. The truncated mRNA with unknown functions may be able to insert itself into human genomes and change our genes.

4. Autoimmune Disorders

As there is no stop signal, in theory, another mRNA in a cell will take over and continue to prolong the “spike protein.” If an mRNA of a self-protein takes over, a mixed type of spike protein with an overlapping region of self-protein will form.

The chance of autoimmunity will increase as our immune system will generate antibodies toward these “spike”-like proteins.

With the release of the adverse event reports of Pfizer’s mRNA COVID-19 vaccine, we see many adverse event reports of autoimmune diseases. In addition to autoimmune liver diseases, there is also autoimmune myocarditis, nephritis, and nervous system damage.

Pfizer vaccine-induced autoimmune injuries, including autoimmune hepatitis, have been summarized in this review, including the original case reports listed below.

Case in Germany: a 52-year-old man developed acute hepatitis twice after receiving two doses of the Pfizer vaccine.

Case in the United States: a healthy 35-year-old woman, who received her first dose of the Pfizer vaccine in the third month postpartum, developed autoimmune hepatitis approximately seven days later. She was diagnosed with vaccine-related drug-induced liver injury with features of autoimmune hepatitis.

Case in Italy: A 43-year-old woman, who developed acute cholestatic hepatitis 15 days after Pfizer vaccination, was considered to have vaccine-induced immune-mediated liver injury.

Case in Spain: A 41-year-old woman, who developed acute hepatitis after receiving the Moderna vaccine, was diagnosed with a vaccine-induced autoimmune liver injury accompanied by severe cholestasis.

Truncted mRNA Is a Serious Quality Issue for COVID-19 mRNA Vaccines

Signatures of shorter RNAs found across different batches of Pfizer mRNA vaccines have demonstrated that substantial degradation occurred during the manufacturing and shipping process, a result discovered after the administration of emergency-authorized Pfizer vaccines.

Like other mRNAs, Pfizer’s vaccine mRNA is fragile, especially when exposed to water. While modifications have made it more stable, mRNA still breaks into pieces of unpredictable length, which explains the observed quality issue of truncated mRNA.

Drug development processes are required to follow strict guidelines for regulatory bodies to justify their human approval.

The regulation is termed ICH guidelines—ICH is the abbreviation of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

ICH issues a complete set of guidelines. The guidelines’ three main categories, quality, safety, and efficacy, are used for authorizing new medicines and monitoring their safety. There is also a fourth category called “multidisciplinary guidelines.”

A main feature of good quality pharmaceutical products is that the quantity, purity, stability, and physical and chemical parameters are stable and consistent across different batches and lots.

The vaccine industry’s current quality control system is well-equipped to catch defects before the fill-finish unit operations. Still, it may miss defects at the fill-finish unit operations and beyond.

While creating the COVID-19 mRNA vaccine, regulations provided by global regulatory agencies laid out requirements for vaccine producer Pfizer-BioNTech. One of the requirements was to prove that the vaccine allowed cells to produce full-length SARS-CoV-2 spike proteins stably.

However, these requirements have not been addressed in a professional, factual manner.

This Issue Contributes to the Disparity of Adverse Events Experienced by Different People

As it is difficult to quantify and qualify impure mRNA components, this truncated mRNA vaccine will cause high variability from different batches and lots.

In Part 1 of this series, Sasha Latypova presented, at 4:01 of her video, her analysis of COVID-19 vaccine shots. She described that “there are lots with almost no adverse effects reported; in some lots, there are thousands of SAEs, hundreds of deaths.”

In her presentation, she also explained an investigation of historical flu shots. There are consistent flu shots across multiple manufacturers, across many lots over 30 years, based on the VAERS data.

She was invited to speak at the Lakaruppropet’s “Pandemic Strategies” conference in Stockholm, Sweden, Jan. 21–22, 2023.

She also published her recorded presentation as her opinion, titled “COVID-19 Countermeasures: Evidence for an intent to harm,” on her LinkedIn page. The entire episode is available here.

She explained the importance of good manufacturing practices (GMP) in the pharmaceutical industry. This means the product should be consistent from one dose (or shot) to the next.

The high variability issue with Pfizer’s mRNA vaccine indicates a defective manufacturing process.

From the report that Pfizer submitted to the FDA in 2020, the RNA integrity ranged from 62 to 86 percent, with a 38.7 percent difference.

Epoch Times Photo
Pfizer mRNA integrity data shows high variability. (FDA)

For Pfizer’s mRNA vaccine, the EMA revised the RNA integrity down to about 50 percent purity.

Brian Gerrish has interviewed Latypova in a UK Column podcast. Gerrish is a former Royal Navy Officer from the Cold War era. He specialized in anti-submarine warfare and conducted operations to locate and track Soviet nuclear submarines in the Norwegian Sea, North Atlantic, and the United States eastern seaboard. He is now a public speaker and investigative journalist with the UK Column newspaper.

Root Cause Behind the Vaccine Issues

It’s strange that global health agencies have not taken strict regulatory measures against Pfizer’s vaccine quality issue.

This is a modern version of “The Emperor’s New Clothes.” People are self-deceiving or passively deceived by others.

Pfizer seems to be the emperor. It not only submitted its falsified Western blots in its regulatory submission of the COVID-19 vaccine but also published its flawless falsified Western blots.

Global health authorities, including the EMA and FDA, seem to be the courtiers. They fully recognized the lack of sufficient experimental data on truncated mRNA and expressed proteins. They were fully aware that Pfizer’s response did not permit a definitive conclusion. Nonetheless, they approved Pfizer’s vaccine.

We are the people on the street, watching all these shows, left speechless.

This is an era of catastrophic moral failure. Once people abandon a moral code, the entire society becomes corrupted.

It is time for people to wake up from the dream of money, profits, and power.

We hope that people will be able to speak up about the truth, spread the truth, return to the tradition of truth and honesty, “do no harm,” and do good to others. Only by doing so can humans sustain themselves and expect a bright future.

◇ References:

COVID-19 countermeasures: Evidence for an intent to harm – FULL

Epoch Health articles are for informational purposes and are not a substitute for individualized medical advice. Please consult a trusted professional for personal medical advice, diagnoses, and treatment. Have a question? Email us at

Yuhong Dong
M.D., Ph.D.
Yuhong Dong, M.D., Ph.D., is a senior medical columnist for The Epoch Times. She is a former senior medical scientific expert and pharmacovigilance leader at Novartis Headquarters in Switzerland, and was a Novartis award winner for four years. She has preclinical research experience in virology, immunology, oncology, neurology, and ophthalmology, and also has clinical experience in infectious disease and internal medicine. She earned her M.D. and a doctorate in infectious diseases at Beijing University in China.
You May Also Like